Leriglitazone Clinical Trials (2026): 1 Studies for Cerebral Adrenoleukodystrophy (cALD)
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
1 Leriglitazone clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 1 indication (including Cerebral Adrenoleukodystrophy (cALD)) and 40 total planned enrollment. 1 Phase 3 Leriglitazone trial are listed. Most recent activity: NCT05819866 (May 2027).
Leriglitazone clinical trials at a glance: phase × recruitment status
| Phase | active not recruiting | Total |
|---|---|---|
| P3 | 1 | 1 |
Leriglitazone pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| CALYX | NCT05819866 | P3 | active not recruiting | Cerebral Adrenoleukodystrophy (cALD) | 40 | — |
All Leriglitazone trials (1)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT05819866 | CALYX | A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adult Male Subjects With Cerebral Adrenoleukodystrophy | P3 | active not recruiting | 40 | Minoryx Therapeutics, S.L. | Jul 2023 |
Leriglitazone clinical trials: frequently asked questions
- How many Leriglitazone clinical trials are there?
- 1 Leriglitazone clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov.
- Are Leriglitazone clinical trials recruiting in 2026?
- No active Leriglitazone trials are recruiting on ClinicalTrials.gov as of the current AACT refresh. Trials may resume; this page is updated daily.
- What conditions is Leriglitazone being studied for?
- Leriglitazone is being studied for Cerebral Adrenoleukodystrophy (cALD). The trials are grouped by indication on this page.
- What phase is Leriglitazone in?
- Leriglitazone clinical trials span 1 Phase 3. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Leriglitazone clinical trials?
- The lead sponsor across the most Leriglitazone trials is Minoryx Therapeutics, S.L.. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Leriglitazoneas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: